Home Blog Page 3589

The Redemption Story of Roger Stone

Mike Lindell Pulls FOX Ads for Not Airing Election Fraud ‘Symposium’

MyPillow CEO Mike Lindell pulled his ads because Fox News refused to run an ad promoting an event linked to claims of widespread fraud in the 2020 presidential election.

QUICK FACTS:
  • The chief executive of MyPillow Inc. said he is pulling his ads from the network after a disagreement over a proposed commercial that would have aired his claims of widespread election fraud, according to The Wall Street Journal (WSJ).
  • Lindell is one of Fox News’ biggest advertisers, notes WSJ.
WHAT MIKE SAID:
  • The MyPillow CEO said he “wanted to cancel the ads as soon as possible and that he had told his ad buyer to inform Fox News,” according to WSJ.
  • He also said he had “asked the network to air a commercial promoting a cyber symposium, which he is scheduled to live stream next month.”
  • Mr. Lindell said the commercial “wouldn’t specifically mention claims of election fraud. But he has said the symposium will prove the 2020 election was stolen from President Donald Trump through manipulation of election machines,” notes WSJ.
WHAT FOX SAID:
  • Fox said in a statement, “It’s unfortunate Mr. Lindell has chosen to pause his commercial time on FOX News given the level of success he’s experienced in building his brand through advertising on the number one cable news network.”
BACKGROUND:
  • Lindell’s Sioux Falls, South Dakota cyber symposium is scheduled for August 10-12.
  • Lindell is also offering $5 million to any symposium attendee who can prove that his cyber data from the November 2020 election is not valid.
  • Lindell said in an interview that he is in possession of “packet captures” (or “PCAPs,” which log activity over a computer network, for example showing votes being “flipped” from Trump to Biden by hackers, as Lindell alleges) from the 2020 U.S. presidential election.
  • “Our country was attacked by China. The election was hacked and we’re gonna have a cyber symposium,” Lindell vowed during a press conference outside a Washington federal court. “And we have all the packet captures for the whole election.”
  • Mr. Lindell says he’s bringing his case to the U.S. Supreme Court.
Mike Lindell Offers $5M to Disprove His 2020 Election Fraud Claims (Video)
Mike Lindell Says ‘Everyone In the World’ Will See 2020 Election Fraud Evidence
Mike Lindell Says He Has ‘Evidence’ China Flipped Votes ‘from Trump to Biden’ in 2020 Election
FULL VIDEO: Mike Lindell TV Releases ‘Irrefutable Election Theft Proof’ Featuring World-Renowned Physicist
WATCH: Mike Lindell’s voting fraud documentary ‘ABSOLUTE PROOF’

Could Larry Elder REALLY defeat Gavin Newsom? (Video)

Capitol Police Are Told To Arrest Any Staffers And Visitors Who Don’t Have Masks On

U.S. Capitol Police (USCP) have been ordered to arrest visitors and staffers not wearing masks on the House side of the Capitol complex.

Police Told To Arrest Maskless Visitors And Staffers

USCP Chief Thomas Manger announced this in a new police memo that was obtained by a member of Congress, according to Fox News.

While officers were told not to arrest members of Congress who refuse to wear masks, they will instead be directed to report the lawmakers’ noncompliance to the House sergeant-at-arms.

Rep. Kat Cammack (R-FL) posted the memo to Twitter on Thursday after she was given it by an unnamed Capitol Police officer.

“This is such an overstep of Speaker Pelosi’s authority to basically make our Capitol Police arrest staff members and report on members [of Congress],” Cammack said of the memo. “It’s absolutely unconscionable that this is where we’re at.”

Cammack and many of her fellow Republican lawmakers have been furious over Speaker Nancy Pelosi’s (D-CA) new mask mandate in the House.

“I cannot comply with this tyrannical order,” Cammack said of it. “This is the people’s house, not Nancy Pelosi’s house.”

Capitol Police Defend Memo

The Capitol Police have defended the memo, claiming that this rule had already been in place and that there’s “no reason” any situation should escalate to the point where someone should be arrested for not wearing a mask.

“Regarding the House rules about masks, there is no reason it should ever come to someone being arrested,” the USCP said. “Anyone who does not follow the rules will be asked to wear a mask or leave the premises. The Department’s requirement for officers to wear masks is for their health and safety.”

Full Story

Woke IOC Declares ‘Transwomen are Women’ as Transgender Kiwi Readies for Weightlifting Debut

The International Olympic Committee (IOC) reaffirmed its full support of transgender athletes Friday when medical director Richard Budgett declared “transwomen are women” and should be included in women’s sport “when we possibly can.”

“After 100 years of promoting women’s sport, it’s up to each of the international federations to ensure that they try and protect women’s sport,” he told a briefing in Tokyo. “Science will help, experience will help, and time will help.”

Budgett spoke as New Zealand weightlifter Laurel Hubbard prepared to become the first openly transgender woman at the Olympics when she competes in the +87kg category on Monday, as AFP reports.

The 43-year-old was born male and competed as a man before transitioning to female in her 30s, taking up the sport at elite level again after meeting IOC guidelines for transgender athletes and sparking a global response.

New Zealand Olympic Committee spokeswoman Ashley Abbott said Hubbard was keeping a low profile in Japan, despite the “particularly high level of interest” in her Olympic debut.

While she acknowledged Hubbard’s appearance raised complex issues, the AFP report said Abbott also pointed out: “We all need to remember that there’s a person behind all these technical questions.”

“As an organization we would look to shield our athlete, or any athlete, from anything negative in the social media space,” she said.

An International Weightlifting Federation spokesman said Hubbard would be under no obligation to speak to journalists after her event.

Critics argue Hubbard has an unfair advantage over female rivals due to physical attributes locked into her body during her formative years as a male.

Full Story

Gavin Newsom Has Reason To Worry

(FiveThirtyEight) Recent polls show the race is tightening and Republican voters are more energized.

It’s official: For only the fourth time in U.S. history, a state will hold an election on whether to recall its governor midterm. The long-expected gubernatorial recall election in California is set for Sept. 14, and 46 candidates (not including the governor himself, Democrat Gavin Newsom) have officially qualified to run. But perhaps the most intriguing development in the race has come in recent polling. After the recall looked uncompetitive for months, evidence has emerged that the race is tightening.

Until last week, there had been no new polls of the recall election in about a month. But since then, we’ve gotten two — and both showed Newsom in danger of being recalled. First, an Emerson College/Nexstar Media survey found that 48 percent of registered voters in California wanted to keep Newsom in office, while 43 percent wanted to recall him. Then, a poll from the University of California, Berkeley, Institute of Governmental Studies co-sponsored by the Los Angeles Times found that 50 percent of likely recall voters wanted to keep Newsom and 47 percent wanted to oust him. These fresh polls — both within the margin of error — differed markedly from a handful of surveys released in May and June that found the recall effort trailing by at least 10 percentage points.

Who casts a ballot in this unusually timed election could be pivotal. The UC Berkeley IGS/Los Angeles Times poll underscored why: Among registered voters, Republicans were far more likely to say they’d vote than Democrats or independents. Eighty percent of Republican registered voters said they were absolutely certain to vote, compared with only 55 percent of Democrats and about half of independents. As such, likely voters were opposed to removing Newsom by only 3 points, while the spread was much wider among all registered voters — 51 percent were opposed to removing him compared with just 36 percent in favor (in line with the pollster’s findings in early May and late January). In fact, Republicans’ enthusiasm for this race is so high that they make up roughly one-third of the survey’s likely electorate, even though they constitute only about one-quarter of California’s registered voters.

Irregularly timed elections, like a gubernatorial recall held in September of an odd year, can produce unexpected results and lopsided electorates. However, there’s one reason why that might not happen in this race: California has extended its pandemic-inspired election-law changes that require ballots to be automatically mailed to all active registered voters through the end of 2021. Mail elections don’t inherently help the Democratic Party, but studies have found that they do increase turnout, which could help insulate Newsom from a scenario where only his most fervent opponents bother to cast a ballot.

It’s tempting to point to COVID-19 as the chief cause for why Newsom is in hot water since the pandemic helped galvanize the recall effort in the first place. The highly contagious delta variant has led to an uptick in cases of COVID-19 in California, and Newsom is now weighing whether to impose statewide restrictions, which could further energize his opposition. (Los Angeles County has already reinstated an indoor mask mandate.) The governor has also had disputes with teachers unions and school administrators over the reopening of schools, and many Californians are still frustrated by the state’s continually changing vaccination-distribution plan. Yet Newsom’s handling of the pandemic might not be his biggest liability. A slightly greater share of likely voters in the Berkeley poll agreed with the statement that Newsom should be recalled “because he has failed to adequately address many of the state’s longstanding problems,” such as homelessness, income inequality and wildfires (48 percent), than agreed with the statement that he should be recalled “because he greatly overstepped his authority as governor when responding to the COVID-19 pandemic” (44 percent).1

In other words, California voters may be displeased with conditions related to COVID-19, but other problems in the state are troubling them, too. Thus, the pandemic may not be solely responsible for what we’ve seen in the polls.

For his part, Newsom is painting the recall as a contest between him and a rash of Trump-supporting Republicans (for instance, the governor has tried to pin the growing number of COVID-19 cases on Republicans and conservative media and their misinformation on vaccines). But this strategy may be complicated by a judge’s ruling on July 12 that Newsom won’t be listed as a Democrat on the official recall ballot.2 Most Californians are probably aware that Newsom is a Democrat, but having his party affiliation spelled out in black and white could have helped him on the margins in this very blue state.

Recent developments in the recall haven’t been all bad news for Newsom. Crucially, his efforts to discourage other prominent Democrats from running in the recall seem to have paid off. Of the 46 candidates running to replace him, only nine are Democrats — and none are established politicians. By contrast, 24 Republican candidates are in the race, as well as two Green Party candidates, one Libertarian Party candidate and 10 independents. This means that, in the event that Newsom is recalled, it’s very likely a Republican will win the race to replace him (the second question on the recall ballot). 

Full Story

Stocks slide as Amazon weighs down tech sector

Amazon Inc.’s revenue topped $100B for third straight quarter.

U.S. stock indexes were lower Friday as investors digested the latest inflation data and sorted through another batch of earnings from high-profile companies.

The Dow Jones Industrial Average fell 63 points, or 0.18%, while the S&P 500 index and the Nasdaq Composite index dropped 0.6% and 1.02%, respectively. All three of the major averages on Thursday ended just below all-time highs. 

TickerSecurityLastChangeChange %
I:DJIDOW JONES AVERAGES34951.27-133.26-0.38%
SP500S&P 5004398.32-20.83-0.47%
I:COMPNASDAQ COMPOSITE INDEX14683.828878-94.43-0.64%

The core personal consumption expenditures price index rose 3.5% annually in June, making for the biggest increase since July 1991. Prices were up 0.4% month over month. Both readings were below what analysts surveyed by Refintiv were expecting. 

In stocks, Amazon Inc.’s quarterly revenue topped $100 billion for the third straight quarter but was below analyst estimates for the first time in three years. The e-commerce giant’s revenue growth forecast for the current quarter came in well below what was expected, with CFO Brian Olsavsky blaming difficult year-over-year comparisons due to the pandemic. 

TickerSecurityLastChangeChange %
AMZNAMAZON.COM, INC.3,353.05-246.87-6.86%

Chevron Corp. reported its second straight quarterly profit as demand for oil products bounced back amid a reopening of the economy and crude prices rose. The oil major reinstated its share buyback program, stating it would purchase shares in the current quarter at a rate of $2 billion to $3 billion per year.  

The rebound in demand and oil prices also benefitted ExxonMobil Corp., which reported its largest quarterly profit in over a year. The company’s bottom line was helped by the cost cuts that were implemented during the pandemic.   

TickerSecurityLastChangeChange %
CVXCHEVRON CORP.101.60-1.04-1.01%
XOMEXXON MOBIL CORP.57.45-1.49-2.53%

Caterpillar Inc., a bellwether for global economic activity, reported equipment sales spiked 31% from a year ago amid strong demand in North America and Latin America. The heavy-equipment maker said demand is likely to remain strong in the current quarter, but that supply chain disruptions will weigh on its operating profit.  

TickerSecurityLastChangeChange %
CATCATERPILLAR, INC.205.02-7.53-3.54%
PGPROCTER & GAMBLE CO.142.90+3.45+2.47%

Proctor & Gamble Co. beat on both the top and bottom lines but warned rising commodity and freight costs would take a bite out of its bottom line during the current fiscal year. The consumer goods producer already announced plans to raise prices for some of its products in September. 

Full Story

FDA Made ‘Dangerous Error’ by Advising Against COVID Antibody Testing

Antibody testing is critical for determining COVID vaccine efficacy and necessity, but FDA continues to recommend against the testing for anyone, including people who already had COVID and those who have been vaccinated against the virus.

On May 19 the U.S. Food and Drug Administration (FDA) released a dangerous and totally inappropriate guidance advising against COVID-19 antibody testing pre- or post-vaccination.

This FDA guidance is dangerous because it discourages and blocks most American physicians from using a gold standard assay for immunity to COVID-19.

But, it is of paramount importance for every American citizen and resident and his/her physician to be able to assess the status of one’s immunity to COVID-19 during this pandemic for two reasons.

First, if a person is found to have no COVID-19 antibodies prior to vaccination, that person will know that he/she is at high risk of developing an infection. In other words, antibody testing would allow determination of medical necessity of COVID-19 vaccination — and being that most persons act rationally given correct information, it is anticipated that most non-immune Americans will seek vaccination when confronted with a negative test.

I have on multiple occasions publicly called on the Biden administration, the FDA commissioner and the CDC to open the door to antibody testing for establishment of medical necessity as a means of combating vaccine hesitancy. Because I believe Americans to be a rational people and, I know from personal experience in medical practice, that when most hesitant Americans are confronted with the FACT that they are NOT immune, a majority choose to get vaccinated.

Americans are a rational people and want to protect themselves from harm. But, by placing barriers to pre-vaccination antibody testing for determination of medical necessity, the Biden administration’s FDA is dangerously, albeit inadvertently, stoking further vaccine hesitancy through this very specific and misguided policy against antibody testing.

Second, the mRNA vaccine is a highly unstable preparation. Thus, it is very likely that a significant number of mRNA vaccine doses entering individual American arms are either partially or completely spoiled — and, thus, ineffective. The fact that FDA’s May 19 guidance is placing a barrier in the way of post-vaccination antibody testing, effectively blocks determination of vaccine efficacy in individual Americans.

This inappropriate FDA action very likely leaves a substantial number of vaccinated citizens susceptible to what would have otherwise been preventable COVID-19 infections had these citizens been provided a pathway to confirm the efficacy of their vaccination.

Because the mRNA vaccines are likely to be susceptible to a significant rate of spoilage, some vaccinated Americans will be either partially or entirely un-immunized against COVID-19 – even though they are fully vaccinated. Because millions of American have vaccinated, tens if not hundreds of thousands, of inadequately immunized people are likely to be roaming around our nation now.

These individuals would be susceptible to so-called “breakthrough infections,” not because the vaccine is generally ineffective, but because they are actually not immune due to a spoilage of their vaccine dose. It is an unassailable clinical fact that such persons would benefit from knowing the status of their COVID-19 antibody immunity — in order to either take extra precautions or to get re-vaccinated.

Unfortunately, the FDA has discouraged vaccinated Americans from confirming the efficacy of their vaccination, effectively leaving the subset subjected to bad vaccinations open to the risk of infection — yet trusting and confident in the efficacy of a dead vaccine.

The incorrect May 19 FDA guidance blocking antibody testing was a shocking pronouncement from a medical perspective. Specifically because antibody testing is the gold standard medical test for immunity against EVERY viral and bacterial pathogen known to humankind — SARS-CoV-2 is no exception. The fact that the medical community has not unanimously objected to this dangerous guidance is a testament to the “group-think” governing our medical establishment and compromising American lives every day in many corners of the healthcare sector. “Group-think” kills!

Full Story

Pfizer Projects $33 Billion in COVID Vaccine Revenues, Driven by Boosters and Vaccines for Kids

Pfizer hiked its projections for COVID vaccine revenues, telling investors this week it expects booster shots, a vaccine targeting the Delta variant and anticipated authorization of its vaccines for children as young as 6 months will drive revenues higher.

Strong sales of its COVID vaccine helped Pfizer nearly double second-quarter revenue and boost profits by 59% — beating Wall Street projections and leading the drug giant to sharply hike its 2021 sales and profit forecasts.

During a July 28 second quarter earnings call, Pfizer told investors the company has increased its revenue projection, now expected to be in the range of $78 to $80 billion.

The company projected revenue from its COVID vaccine alone will hit $33.5 billion — a 29% jump from the previously estimated $26 billion. Pfizer registered $7.8 billion in COVID vaccine sales in the second quarter, bringing total worldwide sales so far this year to $11.3 billion.

The new profit forecast doesn’t include a contract struck last week with the Biden administration to provide an additional 200 million doses to the U.S.

A White House official last week told CNN:

“The federal government is exercising an option in its contract with Pfizer to purchase 200 million doses of the Pfizer vaccine to be delivered between fall 2021 and spring 2022 to prepare for future vaccination needs, including vaccines for children under 12 and possible booster shots if studies show they are necessary.”

The pharmaceutical giant plans to deliver 2.1 billion doses this year and has the capacity to manufacture 4 billion doses next year, CEO Albert Bourla said during the conference call.

The U.S. previously paid $19.50 per dose for the Pfizer-BioNTech vaccine, but Pfizer recently raised the price for the government to $24 per dose.

A Pfizer spokesman said last week in a statement:

“The price for this order accounts for the additional investment necessary to produce, package and deliver new formulations of the vaccine, as well as the increased cost associated with delivering the vaccine in smaller pack sizes to facilitate delivery at individual provider offices, including pediatricians.”

Pfizer based the vaccine’s original price on the need for governments to secure doses and get the virus under control, but CFO Frank D’Amelio said in March the company planned to “get more on price” once the pandemic waned and the company was no longer in a “pandemic pricing environment.”

Pfizer assures investors boosters are coming

Pfizer’s COVID vaccine is currently on pace to be the world’s top-selling drug of all time, Axios reported — and now Pfizer is pushing for people to get a third “booster” shot of its vaccine to combat the Delta variant.

Pfizer said Wednesday it is in ongoing discussions with regulatory agencies regarding a potential third dose booster of the current vaccine and, assuming positive results, anticipates an Emergency Use Authorization (EUA) submission as early as August.

Bourla said the company believes “it is likely that a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection, and studies are underway to evaluate the safety and immunogenicity of a third dose.”

Pfizer said it has new data showing a third dose of its vaccine significantly increases antibody levels against the Delta variant.

But epidemiologists have pointed out that higher antibody levels do not mean higher protection.

Pfizer’s two-dose schedule is already effective against COVID, including the Delta variant, said David Dowdy, an infectious disease epidemiologist at Johns Hopkins. Just because a third dose means more antibodies, doesn’t mean you need one, Dowdy said.

U.S. health agencies said earlier this month there’s no evidence to suggest a booster is needed, but it may be appropriate for special risk groups in the future, including elderly people and transplant recipients. Federal public health officials said they would continue to monitor the situation.

Pfizer executives met privately with U.S. senior scientists and regulators on July 12, to press their case for quick authorization of COVID booster vaccines amid pushback from federal health agencies

Officials said after the meeting that more data — and possibly several more months — would be needed before regulators could determine whether booster shots were necessary, threatening the pharmaceutical giant’s multibillion-dollar revenue stream.

During this week’s call, Pfizer also announced plans to start an immunogenicity and safety study in August to evaluate an updated version of its current vaccine. The new version is specifically designed to target the Delta variant — pending regulatory approval.

During a February earnings call, Bourla told analysts the company could make significant profits by charging higher prices and implementing routine booster doses for new variants of the virus, assuring investors the company didn’t see this as a one-time event, but “as something that’s going to continue for the foreseeable future.”

Vaccines for kids could provide additional revenue stream

Bourla said during the call this week he anticipates that by the end of September, testing in 5- through 11-year-old volunteers will produce the safety and efficacy data needed to seek EUA in that age group, and data on testing in children from 6 months to 5 years old should follow soon after.

This week, Pfizer and Moderna announced they will expand clinical trials of their mRNA vaccines, after the U.S. Food and Drug Administration (FDA) told the vaccine makers the size and scope of their pediatric studies, as initially envisioned, were inadequate to detect rare side effects.

The rare side effects cited by the FDA include myocarditis, an inflammation of the heart muscle, and pericarditis, inflammation of the lining around the heart, multiple people familiar with the trials told The New York Times.

Expanding the pediatric trials means thousands more children as young as 6 months old may soon be recruited and enrolled in COVID vaccine trials.

Moderna’s shot is authorized for emergency use in people 18 and up, and Pfizer’s vaccine is authorized for children as young as 12. No COVID vaccines have yet received EUA approval for children younger than 12.

1...3,5883,5893,590...3,977Page 3,589 of 3,977
This material may not be published, broadcast, rewritten, or redistributed. ©2025 American Faith Media Network. All rights reserved.